Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Paclitaxel + Vantictumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Vantictumab||anti-Fzd7|OMP-18R5||WNT Inhibitor 10||Vantictumab (OMP-18R5) is a monoclonal antibody that targets Frizzled receptors 1, 2, 5, 7, and 8, resulting in decreased Wnt signaling and potentially leading to decreased tumor growth (PMID: 22753465, PMID: 31338636).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||breast cancer||not applicable||Paclitaxel + Vantictumab||Preclinical - Pdx||Actionable||In a preclinical study, Vantictumab (OMP-18R5) worked synergistically with Taxol (paclitaxel) to inhibit tumor growth in patient-derived xenograft models of breast cancer (PMID: 22753465).||22753465|
|Unknown unknown||Her2-receptor negative breast cancer||not applicable||Paclitaxel + Vantictumab||Phase Ib/II||Actionable||In a Phase Ib trial, the combination of Vantictumab (OMP-18R5) and Taxol (paclitaxel) was well-tolerated and demonstrated preliminary efficacy in patients with metastatic HER2-negative breast cancer (J Clin Oncol 34, 2016 (suppl; abstr 2516)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01973309||Phase I||Paclitaxel + Vantictumab||A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer||Completed||USA||0|